Alnylam Pharmaceuticals

Heart
#Alnylam Pharmaceuticals #Cardiovascular disease #Collaboration #Tenaya Therapeutics

Alnylam and Tenaya agree cardiovascular disease collab

Alnylam Pharmaceuticals and Tenaya Therapeutics have agreed a research collaboration to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.  Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets.   In return, Tenaya will receive up to $10 million… Read More

#Business & Investment #News

Patient using blood pressure monitor
#Alnylam Pharmaceuticals #blood #Cardiovascular disease #Hypertension #Phase I trial #RNA

Positive Phase I results for RNAi therapeutic in hypertension

Alnylam Pharmaceuticals has revealed results from its Phase I study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. The results are published in the New England Journal of Medicine (NEJM). The key data showed that… Read More

#News